Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab plus atezolizumab in chemotherapy-naive advanced or metastatic NSCLC
2023-508083-30-00Phase 2Completed
- Sponsor
- Genentech
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing tiragolumab + atezolizumab with atezolizumab + tiragolumab placebo (2 arms). Primary endpoints: Objective response rate and Progression-free survival. Started May 2024; status: completed.
02
Drugs
tiragolumabatezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-508083-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508083-30-00.